EU OKs Bristol-Myers, AstraZeneca diabetes drug

Published



PRINCETON, N.J. (AP) — Drugmakers Bristol-Myers Squibb Co. and AstraZeneca PLC say their experimental diabetes pill has gotten its first major approval, in the European Union.

Forxiga (for-SEE’-gah), a once-a-day pill for adult Type 2 diabetes patients, is the first drug approved in a new class called SGLT2 inhibitors.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.